Understanding how the IL-18-IFNγ pathway affects immunotherapy responses
The IL-18-IFNγ axis predicts response to immunotherapy
['FUNDING_R37'] · SEATTLE CHILDREN'S HOSPITAL · NIH-11061215
This study is looking at how certain markers in the blood can help doctors understand how well CAR T-cell therapy will work for kids with leukemia, so they can better manage treatment and keep patients safe.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11061215 on ClinicalTrials.gov |
What this research studies
This research investigates how the IL-18-IFNγ axis can predict responses to immunotherapy in pediatric leukemia patients receiving CAR T-cell therapy. By analyzing blood samples from patients, the study aims to identify specific biomarkers that indicate the likelihood of treatment success or the risk of severe side effects. The approach includes developing machine learning algorithms to analyze these biomarkers, which could help healthcare providers better prepare for potential complications and improve patient outcomes. Ultimately, this research seeks to enhance the safety and effectiveness of CAR T-cell therapy for children with leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who are receiving CAR T-cell therapy for leukemia.
Not a fit: Patients who are not undergoing CAR T-cell therapy or are over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of treatment responses and reduced side effects for pediatric leukemia patients undergoing CAR T-cell therapy.
How similar studies have performed: Previous research has shown promise in using biomarkers to predict treatment responses in immunotherapy, making this approach both relevant and potentially impactful.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE CHILDREN'S HOSPITAL — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUSTAFSON, HEATHER LEIGH HERD — SEATTLE CHILDREN'S HOSPITAL
- Study coordinator: GUSTAFSON, HEATHER LEIGH HERD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.